ACell Inc. granted MyungMoon Bio Co. Ltd. exclusive rights to market and distribute its wound management matrix products in South Korea.
Included in the deal are the Cytal and MicroMatrix products, which are comprised of naturally-occurring (porcine derived) urinary bladder matrix (UBM). Both facilitate the remodeling of functional tissue and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?